非致死性心肌梗死作为冠心病治疗或预防中全因和心血管死亡替代终点的评估:随机临床试验的荟萃分析
该荟萃分析纳入144项随机临床试验、共1 211 897例患者,评估非致死性心肌梗死能否替代全因或心血管死亡。以决定系数R²≥0.8为替代标准,结果显示非致死性心肌梗死对全因死亡(R²=0.02;95%CI 0.00-0.08)和心血管死亡(R²=0.11;95%CI 0.02-0.27)均未达到替代阈值。各亚组(一级预防、二级预防、混合预防、血运重建试验;不同年代;不同随访时长)结果一致。提示非致死性心肌梗死不能作为冠心病干预试验中全因或心血管死亡的替代终点。
要点
- 非致死性心肌梗死对全因死亡的替代性极低(R²=0.02;95%CI 0.00-0.08),远低于预设的0.8阈值。
- 对心血管死亡的替代性同样不足(R²=0.11;95%CI 0.02-0.27),未达替代标准。
- 一级预防(R²=0.01)、二级预防(R²=0.03)、混合预防(R²=0.001)、血运重建试验(R²=0.21)中均非全因死亡替代终点。
- 不同试验年代(2000年前R²=0.22、2000-2009年R²=0.02、2010年后R²=0.01)及不同随访时长均未达替代阈值。
- 临床决策中不应以非致死性心肌梗死减少推断死亡率获益,试验终点应直接评估死亡。
适用人群与场景
- 纳入至少1000例患者、随访至少24个月的随机临床试验,涵盖一级预防、二级预防、混合预防及血运重建人群。
- 排除标准及具体纳入人群特征原文未提及。
诊断标准与关键阈值
- 替代终点判定标准:试验水平非致死性心肌梗死与全因或心血管死亡的相关性以决定系数R²评估,R²≥0.8视为达到替代标准。
- 非致死性心肌梗死对全因死亡R²=0.02(95%CI 0.00-0.08),对心血管死亡R²=0.11(95%CI 0.02-0.27),均未达0.8阈值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点:非致死性心肌梗死对全因死亡的替代性R²=0.02(95%CI 0.00-0.08),对心血管死亡的替代性R²=0.11(95%CI 0.02-0.27),均未达R²≥0.8的替代标准。
- 亚组结果:一级预防R²=0.01(95%CI 0.001-0.26)、二级预防R²=0.03(95%CI 0.00-0.20)、混合预防R²=0.001(95%CI 0.00-0.08)、血运重建R²=0.21(95%CI 0.002-0.50),均非全因死亡替代终点。
- 年代亚组:2000年前R²=0.22(95%CI 0.08-0.36)、2000-2009年R²=0.02(95%CI 0.00-0.17)、2010年后R²=0.01(95%CI 0.00-0.09),均未达替代标准。
- 随访时长亚组:2.0-3.9年R²=0.004(95%CI 0.00-0.08)、4.0-5.9年R²=0.06(95%CI 0.001-0.16)、≥6.0年R²=0.30(95%CI 0.01-0.55),均未达替代标准。
证据类型、等级与局限
- 证据类型:随机临床试验的荟萃分析(试验水平相关性分析)。
- 局限:仅纳入3本领先期刊的试验,可能存在发表偏倚;为试验水平而非患者水平的替代性评估;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 在冠心病治疗或预防的临床决策及试验解读中,不应将非致死性心肌梗死减少直接等同于全因或心血管死亡获益。
- 评估干预效果时应直接关注死亡率终点,而非以非致死性心肌梗死作为替代。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although nonfatal myocardial infarction (MI) is associated with an increased risk of mortality, evidence validating nonfatal MI as a surrogate end point for all-cause or cardiovascular (CV) mortality is lacking.
OBJECTIVE: To examine whether nonfatal MI may be a surrogate for all-cause or CV mortality in patients with or at risk for coronary artery disease.
DATA SOURCES: In this meta-analysis, PubMed was searched from inception until December 31, 2020, for randomized clinical trials of interventions to treat or prevent coronary artery disease reporting mortality and nonfatal MI published in 3 leading journals.
STUDY SELECTION: Randomized clinical trials including at least 1000 patients with 24 months of follow-up.
DATA EXTRACTION AND SYNTHESIS: Trial-level correlations between nonfatal MI and all-cause or CV mortality were assessed for surrogacy using the coefficient of determination (R2). The criterion for surrogacy was set at 0.8. Subgroup analyses based on study subject (primary prevention, secondary prevention, mixed primary and secondary prevention, and revascularization), era of trial (before 2000, 2000-2009, and 2010 and after), and follow-up duration (2.0-3.9, 4.0-5.9, and ≥6.0 years) were performed.
MAIN OUTCOMES AND MEASURES: All-cause or CV mortality and nonfatal MI.
RESULTS: A total of 144 articles randomizing 1 211 897 patients met the criteria for inclusion. Nonfatal MI did not meet the threshold for surrogacy for all-cause (R2 = 0.02; 95% CI, 0.00-0.08) or CV (R2 = 0.11; 95% CI, 0.02-0.27) mortality. Nonfatal MI was not a surrogate for all-cause mortality in primary (R2 = 0.01; 95% CI, 0.001-0.26), secondary (R2 = 0.03; 95% CI, 0.00-0.20), mixed primary and secondary prevention (R2 = 0.001; 95% CI, 0.00-0.08), or revascularization trials (R2 = 0.21; 95% CI, 0.002-0.50). For trials enrolling patients before 2000 (R2 = 0.22; 95% CI, 0.08-0.36), between 2000 and 2009 (R2 = 0.02; 95% CI, 0.00-0.17), and from 2010 and after (R2 = 0.01; 95% CI, 0.00-0.09), nonfatal MI was not a surrogate for all-cause mortality. Nonfatal MI was not a surrogate for all-cause mortality in randomized clinical trials with 2.0 to 3.9 (R2 = 0.004; 95% CI, 0.00-0.08), 4.0 to 5.9 (R2 = 0.06; 95% CI, 0.001-0.16), or 6.0 or more years of follow-up (R2 = 0.30; 95% CI, 0.01-0.55).
CONCLUSIONS AND RELEVANCE: The findings of this meta-analysis do not appear to establish nonfatal MI as a surrogate for all-cause or CV mortality in randomized clinical trials of interventions to treat or prevent coronary artery disease.
参考来源
- O'Fee K, Deych E, Ciani O, et al. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2021. PMID: 34694318. doi:10.1001/jamainternmed.2021.5726
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。